Randomized, Prospective Comparison of the Outcome of Toric Implantable Contact Lens (TICL) and Q-LASIK for the Correction of Myopia With Astigmatism
Not Applicable
- Conditions
- MyopiaAstigmatism
- Registration Number
- NCT01088568
- Lead Sponsor
- Wenzhou Medical University
- Brief Summary
The objective is to conduct a contralateral prospective clinical study to compare the safety, efficacy, and quality of vision of the STAAR Surgical Co. Toric Implantable Contact Lens TICL) versus Custom Laser Vision Correction (Q-LASIK) in human eyes for the correction of myopia with astigmatism.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Age: 21-45 years old
- Documented stable refraction for at least 1 year
- (-3.0 to -8.0D of myopia with -1.0 to -4.0D of astigmatism or SE from -3.5 to -10D
- BSCVA: 20/20 or better
- Pupil diameter: smaller than 7mm under mesopic condition
- Contact lens discontinued 3 weeks and 1 week for hard and soft wearers respectively
Exclusion Criteria
- Evidence of progressive or acute disease
- Evidence of connective tissue disease or clinically significant atopic disease
- ACD less than 2.8mm from endothelium
- ECC less than 2200 cells/mm2
- Narrow angle of anterior chamber
- Residual stromal thickness less than 280 microns
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Comparing the efficacy, predictability, stability and safety of TICL versus Q-LASIK 1week, 1,3,6 months
- Secondary Outcome Measures
Name Time Method Comparing wavefront aberrometry of TICL vs Q-LASIK Comparing contrast sensitivity of TICL vs Q-LASIK Comparing patient satisfaction of TICL vs Q-LASIK 1, 3, 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms underlying myopia and astigmatism correction with TICL versus Q-LASIK?
How does TICL compare to Q-LASIK in terms of safety and efficacy for myopia with astigmatism correction?
What biomarkers can predict patient response to TICL or Q-LASIK in refractive surgery outcomes?
What are the potential adverse events associated with TICL implantation compared to Q-LASIK procedures?
Are there combination approaches or competitor devices for myopia and astigmatism correction beyond TICL and Q-LASIK?
Trial Locations
- Locations (1)
Eye hospital of Wenzhou Medical College
🇨🇳Wenzhou, Zhejiang, China
Eye hospital of Wenzhou Medical College🇨🇳Wenzhou, Zhejiang, China